Advances in tumor immunotherapy targeting macrophages

Binrui Shi,Meng Du,Zhiyi Chen
DOI: https://doi.org/10.1080/1744666x.2024.2438721
2024-12-12
Expert Review of Clinical Immunology
Abstract:Introduction In recent years, immunotherapy has shown significant therapeutic potential in patients with advanced tumors. However, only a small number of individuals benefit, mainly due to the tumor microenvironment (TME), which provides conditions for the development of tumors. Macrophages in TME, known as tumor-associated macrophages (TAM), are mainly divided into M1 anti-tumor and M2 pro-tumor phenotypes, which play a regulatory role in various stages of tumorigenesis, promote tumorigenesis and metastasis, and cause immunotherapy resistance.
immunology
What problem does this paper attempt to address?